News Releases

Date	Title	Additional Formats
September 26, 2023	Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 5, 2023	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 21, 2023	Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 10, 2023	Phathom Pharmaceuticals Reports Second Quarter 2023 Results
June 12, 2023	Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 9, 2023	Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 1, 2023	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2023	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 23, 2023	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 23, 2023	Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA